DTA (Dopaminergic Therapy for Anhedonia) Study

Depression Clinical Trial

Official title:

Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04723147
• Other study ID #: STUDY00000361
• Secondary ID: 1R61MH121625-01A
• Status: Completed
• Phase: Phase 4
• Start date: January 29, 2021
• Est. completion date: October 11, 2023

Study information

• Verified date: January 2024
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Thirty-five male and female participants with depression, between the ages of 25-55 years of age, will be randomized to two study tracks (A and B) to receive both placebo and three doses of L-DOPA, given in different orders. Increases or decreases in each dose will occur gradually over 6 weeks of the study. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing and functional MRI (fMRI) scans as part of the study. The total length of participation is about 2 months.

Description:

Depression is a widespread disorder (lifetime prevalence >20%). Current antidepressant medications are effective for many patients; however, more than 30% fail to respond. Of the patients that do respond to treatment, some continue to suffer with primary symptoms of depression like an inability to experience pleasure, called anhedonia. In this regard, one biological pathway that may contribute to symptoms of depression and particularly anhedonia is inflammation.

The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Despite evidence of low dopamine function in patients with depression, the ability of existing dopaminergic therapies, like L-DOPA, to affect brain circuits in depression has yet to be explored. This study will help determine the best dose of an FDA-approved medication, Sinemet (L-DOPA) that might be used in the future to treat sub-groups of depressed individuals.

Forty male and female participants with depression, between the ages of 25-55 years of age, will be randomized to two study tracks (A and B) to receive both placebo and three doses of L-DOPA, given in different orders. Increases or decreases in each dose will occur gradually over 6 weeks of the study. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing and functional MRI (fMRI) scans as part of the study. The total length of participation is about 2 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: October 11, 2023
• Est. primary completion date: October 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

• willing and able to give written informed consent;

• men or women, 25-55 years of age

• a primary diagnosis of DSM-V MD, current, as diagnosed by the SCID-I;

• score >10 on the Patient Health Questionnaire [PHQ]-9

• off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine)

• CRP =2 mg/L

• Score >/=2 on the anhedonia question of Patient Health Questionnaire [PHQ]-9

Exclusion Criteria:

• history or evidence (clinical or laboratory) of an autoimmune disorder ;

• history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection; - history of any type of cancer requiring treatment with more than minor surgery;

• unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing);

• history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; history or current bipolar disorder; history or current gambling disorder; substance abuse/dependence within 6 months of study entry (as determined by SCID);

• active suicidal plan as determined by a score >3 on item #3 on the HAM-D; g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms) ;

• a history of a cognitive disorder

• pregnancy or lactation;

• chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or statins;

• use of NSAIDS, glucocorticoids, or statins at any time during the study;

• urine toxicology screen is positive for drugs of abuse,

• any contraindication for MRI scanning; n. intolerance, sensitivity or contraindication to carbidopa-levodopa (including history of narrow-angle glaucoma, melanoma, gastric and/or duodenal ulcers, bleeding disorders, or frequent migraines).

Related Conditions & MeSH terms

• Anhedonia
• Depression
• Depressive Disorder

Intervention

Drug:
• Carbidopa Levodopa
Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
• Placebo
A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.

Locations

Country	Name	City	State
United States	Emory University Hospital	Atlanta	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in targeted ventral striatum to ventromedial prefrontal cortex (VS-vmPFC) connectivity	Patients will undergo resting-state and task-based functional magnetic resonance imaging (fMRI) to calculate functional connectivity (FC) between the ventral striatum (VS) and ventromedial prefrontal cortex (vmPFC). FC is measured as continuous Z scores reflecting the correlation of activity between the brain regions. Higher FC Z scores reflect stronger connectivity.	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA
Secondary	Change in Effort-Expenditure for Rewards Task (EEfRT)	The EEfRT is a widely used, multi-trial task in which participants are given an opportunity on each trial to choose between two different task difficulty levels in order to obtain monetary rewards. EEfRT will be used as an objective measure of motivation and will be administered following MRI scans during the study. The EEfRT is reported as the percent of high effort trials selected. A higher percentage reflects higher motivation for effort expenditure.	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA
Secondary	Change in Inventory of Depressive Symptomatology- Self-Report (IDS-SR)	Anhedonia will be assessed from a subscale of the Inventory of Depressive Symptomatology- Self-Report (IDS-SR). Scores on this 3-question scale range from 0-9 with higher scores reflecting greater anhedonia.	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA
Secondary	Change in Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C )	The Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C) is a clinician administered tool to assess symptoms of anhedonia. The SHAPS-C uses 14 question each rated on a Likert scale of 1-4, with higher scores reflecting greater pathology.	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA
Secondary	Change in Motivation and Pleasure-Self-Report (MAP-SR)	The Motivation and Pleasure-Self-Report (MAP-SR) will be used to capture self-reported aspects of anhedonia and reduced motivation. The scale uses 18 question each rated on a Likert scale of 0-4, with higher scores reflecting greater pathology.	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA
Secondary	Change in Hamilton Depression Rating Scale (HAM-D)	The anhedonia and motivation-related item from the clinician administered Hamilton Depression Rating Scale (HAM-D) (item #7: work and activities) will be used to measure anhedonia. This item is rated on a scale of 0-4 with higher scores reflecting greater pathology	Baseline, 1-week of placebo, and 1-week at each dose of L-DOPA